Parkinson Disease (PD)ETC-PDNCT07297368
Enhanced Tai Chi for Parkinson's Disease (Enhanced Tai Chi PD)
A study testing Enhanced Tai Chi (Enhanced-Tai-Chi-PD) and Usual Treatment (Standard Clinical Care) in people with Parkinson Disease (PD), run by King's College Hospital NHS Trust at 1 site in United Kingdom.
Trial summary
This pilot study evaluates whether a structured, Parkinson's disease-specific Tai Chi programme ("Enhanced Tai Chi") can improve motor and non-motor symptoms in people with Parkinson's disease (PD). Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Parkinson Disease (PD)
- What is being tested?
- Enhanced Tai Chi (Enhanced-Tai-Chi-PD) and Usual Treatment (Standard Clinical Care)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 1 May 2024to 1 Aug 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Idiopathic Parkinson's disease (Hoehn \& Yahr stage I-III)
- Able to stand and participate in movement sessions
- Stable medication dose for ≥ 4 weeks before study entry
Who cannot join
- Atypical or secondary parkinsonism
- Advanced therapies (DBS, apomorphine infusion, jejunal levodopa)
- Dementia (MoCA ≤ 21)
- Other neurological or medical conditions limiting participation
- Inability to commit to scheduled sessions
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Enhanced Tai Chi: A Randomised, Controlled, Single-Site Study of the Effects of Enhanced Tai Chi Training on Motor and Non-Motor Symptoms of Parkinson's Disease: A Pilot Study
This pilot study evaluates whether a structured, Parkinson's disease-specific Tai Chi programme ("Enhanced Tai Chi") can improve motor and non-motor symptoms in people with Parkinson's disease (PD).
PD is a progressive neurological condition associated with motor impairments such as bradykinesia, rigidity, gait disturbance and postural instability, as well as non-motor symptoms including fatigue, pain, mood disturbance, sleep problems and cognitive changes. Although pharmacological treatments improve many motor symptoms, balance and postural control often respond poorly, contributing to falls and reduced independence.
Read more
Enhanced Tai Chi is a tailored programme developed specifically for people with PD, incorporating elements of Tai Chi and Qi Gong focused on balance control, coordination, postural alignment, body awareness and confidence in movement. This single-site, randomised, controlled pilot trial will enrol 30 adults with idiopathic PD (Hoehn \& Yahr stages I-III), randomised in a 2:1 ratio to Enhanced Tai Chi plus usual clinical care or usual clinical care alone.
Participants in the intervention group will complete 36 supervised one-hour sessions over 12 weeks (three sessions per week: one in-person and two delivered remotely), with optional independent practice encouraged. Adherence will be monitored through attendance records. Outcomes will be assessed at baseline, post-intervention and 3-month follow-up. Findings will inform feasibility, acceptability and preliminary efficacy estimates to support the design of a future definitive randomised controlled trial.
Read the detailed description
Background and Rationale
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by motor and non-motor symptoms that substantially affect quality of life and functional independence. While dopaminergic therapies remain the cornerstone of treatment, symptoms such as balance impairment and postural instability often respond incompletely, increasing the risk of falls and injury. Exercise-based interventions are increasingly recommended as adjunctive therapies in PD and may improve mobility, balance, non-motor symptoms and overall quality of life.
Tai Chi and related mind-body practices emphasise slow, controlled movements, weight shifting, postural control, breathing and mental focus. Previous studies suggest Tai Chi may improve balance and reduce falls in people with PD; however, many trials vary in methodological quality and provide limited detail regarding intervention content. Enhanced Tai Chi for Parkinson's (Enhanced-Tai-Chi-PD) was developed to address these limitations by providing a structured, PD-specific programme targeting balance, proprioception, coordination and movement confidence.
Study Design
This is a single-site, randomised, controlled, interventional pilot study. Thirty adults with idiopathic Parkinson's disease will be randomised in a 2:1 ratio to either Enhanced Tai Chi plus usual clinical care or usual clinical care alone. Assessments will be conducted at baseline, after completion of the 12-week intervention period, and at 3-month follow-up.
Intervention
Participants allocated to the intervention arm will attend three one-hour sessions per week for 12 weeks (36 sessions total), comprising one in-person session and two remotely delivered sessions via a secure video platform. The programme consists of seven structured movement components adapted for Parkinson's disease, including Qi Gong-based exercises, silk-reeling movements, balance walking, standing postural exercises and coordinated directional movement forms. Optional independent practice is encouraged. Attendance and adherence will be recorded throughout the intervention period.
Participants in the control arm will continue with usual clinical care as determined by their treating clinicians.
Safety, Data Handling and Oversight
Adverse events, serious adverse events and medication changes will be monitored throughout the study. Study data will be pseudonymised and stored securely in accordance with General Data Protection Regulation (GDPR) requirements and Good Clinical Practice. The study has received appropriate ethical and institutional approvals.
Expected Outcomes
This pilot trial will generate preliminary data on feasibility, adherence and effect size estimates for Enhanced Tai Chi in Parkinson's disease. Results will inform the design and power calculations of a future definitive randomised controlled trial evaluating this intervention as a scalable, low-risk adjunct to standard Parkinson's disease care.
- Conditions
- Parkinson Disease (PD)
- Being tested
- Enhanced Tai Chi (Enhanced-Tai-Chi-PD), Usual Treatment (Standard Clinical Care)
- Keywords
- Parkinson's disease, Tai Chi, Enhanced Tai Chi, Qigong, Mind-body exercise, Non-pharmacological intervention, Balance training, Falls prevention, Motor symptoms, Non-motor symptoms, Quality of life, Pilot study, Feasibility study, Remote intervention, Hybrid trial
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Enhanced Tai Chi (Enhanced-Tai-Chi-PD)Behavioural
Participants assigned to this arm receive Enhanced Tai Chi, a structured mind-body exercise program adapted specifically for people with Parkinson's disease. The program consists of 36 one-hour sessions delivered over 12 weeks (3 sessions/week: 1 in-person studio session and 2 remote sessions via Microsoft Teams). The intervention incorporates seven movement components including Qi Gong, single and double silk-reeling, standing energy/postural work, balance walking, Fa Jin (energy release), and a ten-direction balance form. Sessions focus on balance, postural control, fluid movement, coordination, breathing, and body alignment. Participants are encouraged to complete short additional home practice, and session attendance is logged to monitor compliance.
Usual Treatment (Standard Clinical Care)Other
Participants continue standard clinical care for Parkinson's disease as determined by their treating physician. No Enhanced Tai Chi or other study-specific exercise intervention is provided during the study period.
| Study group | Role | What they receive |
|---|---|---|
| Enhanced Tai Chi + Usual Treatment | Experimental | Participants receive the Enhanced Tai Chi intervention in addition to usual clinical care. Enhanced Tai Chi consists of 36 structured one-hour sessions delivered over 12 weeks (three sessions per week: one in-person session and two remote sessions via Microsoft Teams). Participants are encouraged to undertake short additional home practice. Attendance is recorded to monitor adherence. Usual clinical care continues as directed by the treating physician. Receives: Behavioral: Enhanced Tai Chi (Enhanced-Tai-Chi-PD) |
| Usual Treatment (Control) | Active comparator | Participants continue standard clinical care as determined by their treating physician (stable dopaminergic medications, and referrals to physiotherapy, occupational therapy, speech and language therapy as clinically needed). No Tai Chi is provided during the study period. Receives: Other: Usual Treatment (Standard Clinical Care) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in motor symptoms (MDS-UPDRS Part III)
Clinician-rated assessment using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III (MDS-UPDRS III), performed in the ON medication state. Total score ranges from 0 to 132, with higher scores indicating greater motor impairment. Reductions in score indicate improvement in motor symptoms.
Measured: Baseline to 12 weeks (end of intervention)
Secondary outcomes (16)
Change in non-motor symptoms (MDS Non-Motor Symptoms Scale)
Assesses frequency and severity of non-motor symptoms in Parkinson's disease. Total score ranges from 0 to 360, with higher scores indicating greater non-motor symptom burden. Interpretation of scores is as follows: Mild (1-44 points), Moderate (45-78 points), Severe (79-112 points), and very severe (>112).
Measured: Baseline, 12 weeks, and 3-month follow-up
Patient Global Impression of Change (PGIC)
Participant-reported overall perception of change in health status. Scored on a 7-point Likert scale (1 = very much improved, 4 = no change, 7 = very much worse). Lower scores indicate perceived improvement, while higher scores indicate worsening.
Measured: 12 weeks and 3-month follow-up
Change in quality of life (PDQ-8)
Self-reported measure of health-related quality of life. Total score ranges from 0 to 32, with lower scores indicating better quality of life. A decrease in score reflects improvement. For this study, a meaningful change is defined as a change of 5-7 points, indicating clinical significant impact to quality of life.
Measured: Baseline, 12 weeks, and 3-month follow-up
Change in cognitive function (MoCA)
Brief cognitive screening tool. Total score ranges from 0 to 30, with higher scores indicating better cognitive function. Scores 26-30 (normal), 18-25 (mild cognitive impairment), 10-17 (moderate cognitive impairment), and <10 (severe cognitive impairment). Increases in score suggest improvement or preservation of cognitive function.
Measured: Baseline, 12 weeks, and 3-month follow-up
Change in pain (King's Parkinson's Disease Pain Scale - KPPS)
Clinician-rated assessment of Parkinson's disease-related pain across multiple domains. Total score ranges from 0 to 168, with higher scores indicating greater pain severity. Lower scores represent improvement in pain symptoms. Interpretation for this study: score 0 (no pain), scores 17-34 (mild to moderate), 68-70 (moderate to severe). Minimal clinical important difference is measured by a change of 3 points to indicate meaningful change.
Measured: Baseline, 12 weeks, and 3-month follow-up
Change in sleep disturbance (PD Sleep Scale-2)
Assesses sleep disturbances in Parkinson's disease. Total score ranges from 0 to 60, with higher scores indicating worse sleep quality. For this study, meaningful change is defined as a decrease of at least 3.44 points for improvement or an increase of at least 2.07 points for worsening.
Measured: Baseline, 12 weeks, and 3-month follow-up
Change in fatigue (Parkinson's Fatigue Scale-16)
Self-reported fatigue severity scale. Total score ranges from 16 to 80, with higher scores indicating greater fatigue.
Measured: Baseline, 12 weeks, 3-month follow-up
Change in anxiety and depression (Hospital Anxiety and Depression Scale - HADS)
Self-reported assessment of anxiety and depression using two subscales (HADS-A and HADS-D). Each subscale ranges from 0 to 21, with higher scores indicating greater symptom severity. Scores 0-7 (normal), 8-10 (mild/borderline), 11-14 (moderate), and 15-21 (severe). Lower scores indicate improvement in anxiety and/or depressive symptoms. Meaningful change is defined as change of 2 points.
Measured: Baseline, 12 weeks, and 3-month follow-up
Change in apathy (Apathy Scale - AS)
Self-reported measure of apathy. Total score ranges from 0 to 42, with higher scores indicating greater apathy. PD patients with scores over 14 suggest clinically significant meaningful apathy. Lower scores represent improvement in motivational symptoms.
Measured: Baseline, 12 weeks, 3-month follow-up
Change in physical activity level (PASE)
Self-reported assessment of physical activity over the previous week. Scores typically range from 0 to >400, with higher scores indicating greater levels of physical activity. Increases in score indicate higher activity levels.
Measured: Baseline, 12 weeks, 3-month follow-up
Change in global clinical severity (CISI-PD)
Clinician-rated global assessment across four domains (motor signs, disability, cognitive status, and complications). Each domain is scored from 0 to 6, giving a total score range of 0 to 24, with higher scores indicating greater disease severity. A reduction in total score over time indicates clinical improvement.
Measured: Baseline, 12 weeks, 3-month follow-up
Change in balance performance (Berg Balance Scale)
Clinician-rated 14-item assessment of balance performance. Total score ranges from 0 to 56, with higher scores indicating better balance. For this study we consider 0-20 (wheelchair/ high fall risk), 21-40 (needing aids/ moderate risk), 41-56 (independent, low risk), with scores <45 indicating increased risk of falls for the PD population. Increases in score indicate improvement in balance ability.
Measured: Baseline, 12 weeks, 3-month follow-up
Change in mobility (Timed Up and Go - TUG)
Performance-based assessment measuring the time (in seconds) required to stand from a seated position, walk 3 meters, turn, return, and sit down. Lower times indicate better mobility and functional performance. For this study with PD patients our scoring is as follows: <12 seconds (good mobility), 12-14 seconds (differentiates PD fallers vs non-fallers, with higher end being riskier), >14 seconds (high risk for fall), >20 seconds (needs assistance for basic transfer), and >30 seconds (limited mobility, decreased independence).
Measured: Baseline, 12 weeks, 3-month follow-up
Change in walking speed (10-Meter Walk Test)
Performance-based assessment measuring the time (in seconds) to walk 10 meters at a comfortable pace. Lower times indicate faster walking speed and improved gait performance. For this study, there needs to be a minimum detectable change of approximately 0.18 m/s (comfortable) or 0.25 m/s (fast) to show real improvement, not just testing variation.
Measured: Baseline, 12 weeks, 3-month follow-up
Number of monthly falls
Self-reported number of falls recorded using participant-maintained fall diaries. Higher values indicate increased fall frequency, while reductions indicate improvement in fall risk.
Measured: Baseline, 12 weeks, 3-month follow-up
Feasibility / compliance with intervention
17a. Intervention adherence: Percentage of scheduled Enhanced Tai Chi sessions attended during the intervention period. Values range from 0% to 100%, with higher percentages indicating better adherence.
17b. Intervention tolerability: Proportion of participants who discontinue the intervention due to tolerability issues. Values range from 0 to 100%, with lower percentages indicating better tolerability.
Measured: Continuous over 12-week intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Dec 2025
- Study start1 May 2024
- Primary completion1 Apr 2026 (estimated)
- Study completion1 Aug 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson Disease (PD)Studies of the same condition, open and under way.
- More trials run by King's College Hospital NHS TrustThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Participants are randomized in a 2:1 ratio to either the Enhanced Tai Chi intervention group (Enhanced-Tai-Chi-PD + usual treatment) or the control group (usual treatment only). The intervention group receives 36 sessions over 12 weeks (one in-person session and two remote sessions per week via Microsoft Teams). The control group continues with usual clinical care per local pathway. No crossover occurs between groups.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- King's College Hospital NHS Trust
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Julie Whitney, MSc, Principal investigator, King's College Hospital NHS Trust
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07297368
- Sponsor's protocol ID
- 24/WS/0099
- Acronym
- ETC-PD
- Status last verified
- Dec 2025
- First submitted
- 9 Dec 2025
- Last updated
- 31 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data will be shared upon reasonable request after publication of primary results. Data access request can be made by contacting our Research Data team for the study (kch-tr.taichi.inbox@nhs.net)
Study at a glance
From the registry record, last updated by the sponsor on 31 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Enhanced Tai Chi: A Randomised, Controlled, Single-Site Study of the Effects of Enhanced Tai Chi Training on Motor and Non-Motor Symptoms of Parkinson's Disease: A Pilot Study
- ClinicalTrials.gov ID
- NCT07297368
- Acronym / sponsor ID
- ETC-PD / 24/WS/0099
- Conditions
- Parkinson Disease (PD)
- Keywords
- Parkinson's disease, Tai Chi, Enhanced Tai Chi, Qigong, Mind-body exercise, Non-pharmacological intervention, Balance training, Falls prevention
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 30 participants (actual)
- Lead sponsor
- King's College Hospital NHS TrustUniversity, hospital or other
- Study start
- 1 May 2024 (actual)
- Primary completion
- 1 Apr 2026 (estimated)
- Study completion
- 1 Aug 2026 (estimated)
- First posted
- 22 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This pilot study evaluates whether a structured, Parkinson's disease-specific Tai Chi programme ("Enhanced Tai Chi") can improve motor and non-motor symptoms in people with Parkinson's disease (PD).
PD is a progressive neurological condition associated with motor impairments such as bradykinesia, rigidity, gait disturbance and postural instability, as well as non-motor symptoms including fatigue, pain, mood disturbance, sleep problems and cognitive changes. Although pharmacological treatments improve many motor symptoms, balance and postural control often respond poorly, contributing to falls and reduced independence.
Enhanced Tai Chi is a tailored programme developed specifically for people with PD, incorporating elements of Tai Chi and Qi Gong focused on balance control, coordination, postural alignment, body awareness and confidence in movement. This single-site, randomised, controlled pilot trial will enrol 30 adults with idiopathic PD (Hoehn \& Yahr stages I-III), randomised in a 2:1 ratio to Enhanced Tai Chi plus usual clinical care or usual clinical care alone.
Participants in the intervention group will complete 36 supervised one-hour sessions over 12 weeks (three sessions per week: one in-person and two delivered remotely), with optional independent practice encouraged. Adherence will be monitored through attendance records. Outcomes will be assessed at baseline, post-intervention and 3-month follow-up. Findings will inform feasibility, acceptability and preliminary efficacy estimates to support the design of a future definitive randomised controlled trial.
Detailed description
Background and Rationale
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by motor and non-motor symptoms that substantially affect quality of life and functional independence. While dopaminergic therapies remain the cornerstone of treatment, symptoms such as balance impairment and postural instability often respond incompletely, increasing the risk of falls and injury. Exercise-based interventions are increasingly recommended as adjunctive therapies in PD and may improve mobility, balance, non-motor symptoms and overall quality of life.
Tai Chi and related mind-body practices emphasise slow, controlled movements, weight shifting, postural control, breathing and mental focus. Previous studies suggest Tai Chi may improve balance and reduce falls in people with PD; however, many trials vary in methodological quality and provide limited detail regarding intervention content. Enhanced Tai Chi for Parkinson's (Enhanced-Tai-Chi-PD) was developed to address these limitations by providing a structured, PD-specific programme targeting balance, proprioception, coordination and movement confidence.
Study Design
This is a single-site, randomised, controlled, interventional pilot study. Thirty adults with idiopathic Parkinson's disease will be randomised in a 2:1 ratio to either Enhanced Tai Chi plus usual clinical care or usual clinical care alone. Assessments will be conducted at baseline, after completion of the 12-week intervention period, and at 3-month follow-up.
Intervention
Participants allocated to the intervention arm will attend three one-hour sessions per week for 12 weeks (36 sessions total), comprising one in-person session and two remotely delivered sessions via a secure video platform. The programme consists of seven structured movement components adapted for Parkinson's disease, including Qi Gong-based exercises, silk-reeling movements, balance walking, standing postural exercises and coordinated directional movement forms. Optional independent practice is encouraged. Attendance and adherence will be recorded throughout the intervention period.
Participants in the control arm will continue with usual clinical care as determined by their treating clinicians.
Safety, Data Handling and Oversight
Adverse events, serious adverse events and medication changes will be monitored throughout the study. Study data will be pseudonymised and stored securely in accordance with General Data Protection Regulation (GDPR) requirements and Good Clinical Practice. The study has received appropriate ethical and institutional approvals.
Expected Outcomes
This pilot trial will generate preliminary data on feasibility, adherence and effect size estimates for Enhanced Tai Chi in Parkinson's disease. Results will inform the design and power calculations of a future definitive randomised controlled trial evaluating this intervention as a scalable, low-risk adjunct to standard Parkinson's disease care.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- Participants are randomized in a 2:1 ratio to either the Enhanced Tai Chi intervention group (Enhanced-Tai-Chi-PD + usual treatment) or the control group (usual treatment only). The intervention group receives 36 sessions over 12 weeks (one in-person session and two remote sessions per week via Microsoft Teams). The control group continues with usual clinical care per local pathway. No crossover occurs between groups.
| Arm | Type | Receives |
|---|---|---|
| Enhanced Tai Chi + Usual Treatment | Experimental | Behavioral: Enhanced Tai Chi (Enhanced-Tai-Chi-PD)Participants receive the Enhanced Tai Chi intervention in addition to usual clinical care. Enhanced Tai Chi consists of 36 structured one-hour sessions delivered over 12 weeks (three sessions per week: one in-person session and two remote sessions via Microsoft Teams). Participants are encouraged to undertake short additional home practice. Attendance is recorded to monitor adherence. Usual clinical care continues as directed by the treating physician. |
| Usual Treatment (Control) | Active comparator | Other: Usual Treatment (Standard Clinical Care)Participants continue standard clinical care as determined by their treating physician (stable dopaminergic medications, and referrals to physiotherapy, occupational therapy, speech and language therapy as clinically needed). No Tai Chi is provided during the study period. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Idiopathic Parkinson's disease (Hoehn \& Yahr stage I-III)
- Able to stand and participate in movement sessions
- Stable medication dose for ≥ 4 weeks before study entry
Key exclusion criteria (5 listed)
- Atypical or secondary parkinsonism
- Advanced therapies (DBS, apomorphine infusion, jejunal levodopa)
- Dementia (MoCA ≤ 21)
- Other neurological or medical conditions limiting participation
- Inability to commit to scheduled sessions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Enhanced Tai Chi (Enhanced-Tai-Chi-PD)Participants assigned to this arm receive Enhanced Tai Chi, a structured mind-body exercise program adapted specifically for people with Parkinson's disease. The program consists of 36 one-hour sessions delivered over 12 weeks (3 sessions/week: 1 in-person studio session and 2 remote sessions via Microsoft Teams). The intervention incorporates seven movement components including Qi Gong, single and double silk-reeling, standing energy/postural work, balance walking, Fa Jin (energy release), and a ten-direction balance form. Sessions focus on balance, postural control, fluid movement, coordination, breathing, and body alignment. Participants are encouraged to complete short additional home practice, and session attendance is logged to monitor compliance. | Behavioural | Enhanced Tai Chi + Usual Treatment |
| Usual Treatment (Standard Clinical Care)Participants continue standard clinical care for Parkinson's disease as determined by their treating physician. No Enhanced Tai Chi or other study-specific exercise intervention is provided during the study period. | Other | Usual Treatment (Control) |
Primary outcome
Change in motor symptoms (MDS-UPDRS Part III)
Time frame: Baseline to 12 weeks (end of intervention)
Clinician-rated assessment using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III (MDS-UPDRS III), performed in the ON medication state. Total score ranges from 0 to 132, with higher scores indicating greater motor impairment. Reductions in score indicate improvement in motor symptoms.
16 secondary outcomes
Change in non-motor symptoms (MDS Non-Motor Symptoms Scale)
Time frame: Baseline, 12 weeks, and 3-month follow-up
Patient Global Impression of Change (PGIC)
Time frame: 12 weeks and 3-month follow-up
Change in quality of life (PDQ-8)
Time frame: Baseline, 12 weeks, and 3-month follow-up
Change in cognitive function (MoCA)
Time frame: Baseline, 12 weeks, and 3-month follow-up
Change in pain (King's Parkinson's Disease Pain Scale - KPPS)
Time frame: Baseline, 12 weeks, and 3-month follow-up
Change in sleep disturbance (PD Sleep Scale-2)
Time frame: Baseline, 12 weeks, and 3-month follow-up
Change in fatigue (Parkinson's Fatigue Scale-16)
Time frame: Baseline, 12 weeks, 3-month follow-up
Change in anxiety and depression (Hospital Anxiety and Depression Scale - HADS)
Time frame: Baseline, 12 weeks, and 3-month follow-up
Change in apathy (Apathy Scale - AS)
Time frame: Baseline, 12 weeks, 3-month follow-up
Change in physical activity level (PASE)
Time frame: Baseline, 12 weeks, 3-month follow-up
Change in global clinical severity (CISI-PD)
Time frame: Baseline, 12 weeks, 3-month follow-up
Change in balance performance (Berg Balance Scale)
Time frame: Baseline, 12 weeks, 3-month follow-up
Change in mobility (Timed Up and Go - TUG)
Time frame: Baseline, 12 weeks, 3-month follow-up
Change in walking speed (10-Meter Walk Test)
Time frame: Baseline, 12 weeks, 3-month follow-up
Number of monthly falls
Time frame: Baseline, 12 weeks, 3-month follow-up
Feasibility / compliance with intervention
Time frame: Continuous over 12-week intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Dec 2025.
- Individual participant dataSharing planned: Yes. De-identified individual participant data will be shared upon reasonable request after publication of primary results. Data access request can be made by contacting our Research Data team for the study (kch-tr.taichi.inbox@nhs.net)
Related trials for Parkinson Disease (PD)
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Active, not recruitingPhase 1/2
Clinical Safety and Efficacy of Umbilical Cord Mesenchymal Stromal Cells-derived Exosomes in Patients With Parkinson's Disease
Parkinson Disease (PD)
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
Active, not recruitingPhase 2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Carcinoma, Non-Small-Cell Lung
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Julie Whitney, MSc principal investigator
King's College Hospital NHS Trust
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Enhanced Tai Chi (Enhanced-Tai-Chi-PD) and Usual Treatment (Standard Clinical Care) in people with Parkinson Disease (PD), run by King's College Hospital NHS Trust at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 31 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in motor symptoms (MDS-UPDRS Part III) (time frame: Baseline to 12 weeks (end of intervention)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Dec 2025.